Literature DB >> 9140114

Induction of specific cytotoxic T lymphocytes against autologous brain tumor by crossreactive allo-tumor cell stimulation.

S Saitoh1, M Kurisaka, K Mori, N Maeda, S Fujimoto.   

Abstract

Cytotoxic T lymphocytes (CTL) against autologous malignant brain tumor were generated in peripheral blood lymphoid cells (PBL) prepared from a patient with a malignant brain tumor by stimulation of the cultured PBL for 7 days with attenuated crossreactive malignant melanoma (MM2) cells pretreated with mitomycin C. The crossreactive MM2 cells were effective for antigen stimulation for CTL induction in place of autologous glioblastoma cells, which are difficult to expand in culture. The optimal ratio between nylon wool-passed T lymphocytes and nylon wool-adherent accessory cells to induce CTL in the patient's PBL was found to be 25 to 1. In vitro-activated CTLs induced by MM2 were cytotoxic not only to MM2, but also to the autologous tumor cells in an HLA class I-restricted manner, and their surface phenotype was found to be CD3+ and CD8+. CTL therapy using cross-reactive allogeneic tumor cells as the stimulator could be clinically valuable to treat malignant brain tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140114      PMCID: PMC5921378          DOI: 10.1111/j.1349-7006.1997.tb00380.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  22 in total

Review 1.  Mechanism of lymphocyte-mediated cytotoxicity.

Authors:  P A Henkart
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

Review 2.  Studies Utilizing murine T cell clones: Ir genes, Ia antigens and MLR stimulating determinants.

Authors:  C G Fathman; M Kimoto
Journal:  Immunol Rev       Date:  1981       Impact factor: 12.988

Review 3.  Cytolytic T lymphocytes.

Authors:  M Nabholz; H R MacDonald
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

Review 4.  Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.

Authors:  T Boon; P Coulie; M Marchand; P Weynants; T Wölfel; V Brichard
Journal:  Important Adv Oncol       Date:  1994

5.  Abnormal migration of T lymphocyte clones.

Authors:  M O Dailey; C G Fathman; E C Butcher; E Pillemer; I Weissman
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

6.  Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (Interleukin 2): in vivo activity.

Authors:  G B Mills; G Carlson; V Paetkau
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

Review 7.  Genes coding for tumor antigens recognized by human cytolytic T lymphocytes.

Authors:  P G Coulie; P Weynants; F Lehmann; J Herman; V Brichard; T Wölfel; A Van Pel; E De Plaen; F Brasseur; T Boon
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-08

8.  The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor.

Authors:  C Siepl; S Bodmer; K Frei; H R MacDonald; R De Martin; E Hofer; A Fontana
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

9.  Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif.

Authors:  E A Wiedenfeld; M Fernandez-Viña; J A Berzofsky; D P Carbone
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

10.  Augmentation of human cytotoxic T lymphocytes against autologous tumor by a factor released from human monocytic leukemia cell line.

Authors:  N Maeda; S Hamasato; H Miyazawa; M Takata; H Yamamoto; S Fujimoto
Journal:  Jpn J Cancer Res       Date:  1989-06
View more
  1 in total

1.  Adoptive immunotherapy using specific cytotoxic T lymphocytes against human lung-cancer-engrafted severe combined immunodeficiency mice.

Authors:  S Imahayashi; I Yoshino; R Eifuku; M Takenoyama; T Hanagiri; K Yasumoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.